AI healthcare enters speed up development phase

Medical health has become an important research and application field of artificial intelligence. In recent years, the major technology giants and many new venture companies have laid out the AI medical field, the application of artificial intelligence in the field of medical health is in full swing. The industry believes that AI medical has entered the stage of accelerated development. According to the third party Research Institute, the AI medical market in 2018 is expected to reach 20 billion yuan. However, data, talents and standards still play an important role in restricting the development of AI.
 
 
 
 
 
Dr. AI competed for appearance.
 
 
 
Artificial intelligence in the field of medical and health applications scenarios mainly include auxiliary diagnosis and treatment, drug mining, medical robots, precision medicine and so on. At present, the application of auxiliary diagnosis and treatment is the most extensive. In recent years, intelligent medical assistant products and services have mushroomed.
 
 
 
"The essential role of artificial intelligence is to improve efficiency, the application of artificial intelligence in the field of diagnosis and treatment can increase efficiency." In an exclusive interview with reporters from China Securities News on September 19, Zhang Shaopian, founder and chief executive of Senyi Intelligence, told the Shanghai AI Auxiliary Clinical Diagnosis and Drug Safety Summit Forum that the main challenge facing medical services lies in the inadequate supply of medical resources. One solution is to provide new supplies such as building new doctors. The two is to improve the efficiency of the existing supply. The company's niche is to help medical staff manage high-risk patients and warn adverse events efficiently through automatic monitoring with artificial intelligence, saving time and reducing error rates. At present, the company has started cooperation with more than 30 top three hospitals.
 
 
 
The annual meeting of the Chinese Society of Clinical Oncology (CSCO) in 2018, held from September 19 to 23, is planning to launch a "man-machine competition" in the medical field, with more than 30,000 Chinese doctors competing against a tumor intelligent diagnosis and treatment system. Jiang Zefei, secretary-general of the Chinese Society of Clinical Oncology, said that in 2018, the Chinese Society of Clinical Oncology began to promote artificial intelligence in the field of first-line cancer treatment in China. The tumor population and social environment in China have their own characteristics and cannot be fully guided by foreign guidelines. By building a Chinese version of the "IBM Watson" system, patients and doctors can map out the entire treatment path, as well as meet the long-term management needs of chronic cancer diseases, to better manage data, just like using navigation.
 
 
 
Drug mining, medical robots and other fields are not as rapid as the development of auxiliary diagnosis and treatment, but there are also many domestic enterprises involved. Qiao Hui, general manager of Harbin Industrial Intelligence, told China Securities News that one of its products in the field of artificial intelligence robots is a blood-collecting robot, which has been developed in cooperation with Veebot, a US company.
 
 
 
 
 
Constraint factors need to be broken through
 
 
 
As one of the participants in the industry, Zhang Shaodian's great feeling is that AI medical has entered a stage of rapid development in recent years. He predicts that there will be a large-scale application landing in 2-3 years.
 
 
 
On the one hand, the major technology giants have entered this field, overseas IBM, Google and other companies to join the domestic BAT layout; on the other hand, the market emerged a number of entrepreneurial companies. CB Insights, a market research firm, recently reported that in the private equity market, medical AI start-ups have raised $4.3 billion through 576 transactions since 2013, leading all other sectors in AI financing.
 
 
 
According to a report released by the Institute of Prospective Industries, the market for medical artificial intelligence in China will reach 9.661 billion yuan in 2016 and 20 billion yuan in 2018.
 
 
 
Zhang Shaodian said that the scale of China's medical information market was about 35 billion yuan, and the annual compound growth rate reached 20%. At present, the vast majority of information technology does not belong to the field of artificial intelligence, but the future of intelligence will be one of the key points. In addition, the two major market volume of new drug research and development, medical insurance and fee control should not be underestimated. For the future development of the industry, he believes that the AI medical field is hard to get the pattern of winner take all. Considering the wide coverage of the medical field, the long industrial chain links and the diverse application scenarios, this gives the market participants the space of dislocation competition. At present, except for the crowded video track, the rest areas are vast blue ocean.
 
 
 
Despite the rapid development of AI, its application is still subject to many constraints. Dong Chengcheng, vice chairman of medical informatics at the Chinese Medical Association, said data, algorithms and computational power were the key to the development of AI medicine. Among them, the emphasis is on data. The quality of large data determines whether artificial intelligence can be "intelligent" in the future. It needs to attach great importance to the construction of medical data platform.
 
 
 
In addition to the challenges posed by unstructured and non-standardized data, Zhang said that in practice, it often happens that IT doesn't understand the clinic well, and clinicians don't understand IT well enough, which requires more collision and integration. In addition, the standard system needs to be improved. This is another problem facing AI's medical development.

Copyright © 2018-2020 Jiangsu Opera Medical Supplies Co., Ltd Copyright    ICP prepared No.14055262-1